Bridge Biotec is an ambitious company aiming to be revenue generating within 3 years, by taking the lead project to regulatory approval for clinical trials (IND/CTA), or 5 years after clinical proof of concept with our lead compound. This could be via out-licencing or trade sale, or by any suitable route.
We have licenced two very important components that we plan to combine to form a range of therapies aimed at treating serious inflammatory diseases:
Highly potent and highly specific novel peptide (“small protein”) anti-inflammatory therapeutics
Safe, nanoparticle delivery polmer, that will take the peptides into human cells and switch off inflammation
By combining these two important components to form its lead compound JEL3108, we will create a new medicine to more safely and effectively treat life threatening and disabling inflammatory diseases.
Bridge is currently seeking a total of $12,000,000 investment over the next 3 years, to drive the lead compound through to regulatory approval of clinical trials (IND/CTA). Read more investment detail here.
Bridge was incorporated in late 2016 to reserve the name. In 2017 Bridge gained exclusive world-wide licences to develop Astra-Zeneca's peptide compounds and a clinically safe nano-particle delivery technology. We will take this combination from preclinical research to de-risked human clinical proof of concept trials, over the next 5 years, by employing cutting-edge adaptive clinical trial designs to expedite clinical trial delivery. In this way, Bridge aims to avoid much of the late stage efficacy failures experienced by large pharma companies.
If you would like to make a donation to Bridge Biotec to help us advance our research into inflammation treatments, please use the donate button below.